...submit an NDA for both indications six months later. Also in Phase III testing are surotomycin...
...like patients who have relapsed multiple times. Dificid should be a good complement for Cubist's surotomycin...

...FDA granted Fast Track designation for surotomycin to treat Clostridium difficile-associated diarrhea (CDAD). Surotomycin is an...
...Dec. 17, 2012). Cubist Pharmaceuticals Inc. (NASDAQ:CBST), Lexington, Mass. Product: Surotomycin ( CB-315 ) (formerly CB-183,315...

...in revenues for the first nine months of 2012. The other Phase III program is CB-315...

...for CB-315 to treat Clostridium difficile-associated diarrhea (CDAD) and CXA-201 to treat complicated intra-abdominal infection. CB-315...
...signed into law earlier this year. Cubist Pharmaceuticals Inc. (NASDAQ:CBST), Lexington, Mass. Product: CB-315 (formerly CB-183,315...

...of a pair of identical, double-blind, international Phase III trials to compare 250 mg twice-daily CB-315...
...10 days in 608 patients each. Cubist Pharmaceuticals Inc. (NASDAQ:CBST), Lexington, Mass. Product: CB-315 (formerly CB-183,315...

...two products in Phase II testing: CB-5945 , an OPRM1 antagonist for opioid-induced constipation; and CB-183,315...

...UTI). The company has two products in Phase II testing: CB-5945 for opioid-induced constipation; and CB-183,315...

...complicated urinary tract infections (cUTIs) by year end (see B17) . Separately, Cubist said its CB-183,315...
...company plans to announce by year end whether it will start Phase III testing of CB-183,315...

...Canadian Phase II trial in 209 patients showed that twice-daily 125 and 250 mg oral CB-183,315...
...lower recurrence rate vs. Vancocin (17% vs. 36%, p=0.035), but low-dose CB-183,315 did not (28%). CB-183,315...
...Cubist plans to announce a formal decision on whether to start Phase III testing with CB-183,315...